Response to and Survival after First-Line FOLFIRINOX or Gemcitabine/Nab-Paclitaxel for Localized Pancreatic Ductal Adenocarcinoma

Introduction: We sought to evaluate radiographic and serologic measures of response to first-line chemotherapy with FOLFIRINOX or gemcitbine/nab-paclitaxel (GA) for localized pancreatic cancer (PDAC) and their association with survival Methods: All patients diagnosed with localized PDAC at MD Anderson between 2010 and 2017 who received at least 3 cycles of first-line chemotherapy with FOLFIRINOX or GA were included. 495 patients were treated...